Stockscreener 앱 받기
5.35
6.57%
0.33
시장 영업 전:
5.55
0.20
+3.74%
Verrica Pharmaceuticals Inc 주식(VRCA)의 최신 뉴스
Verrica Pharmaceuticals Inc (VRCA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRCA|Verrica Pharmaceuticals Inc|Price:5.020|Chg%:-0.420 - TradingKey
TradingKey - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verrica Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc (VRCA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Verrica grants Medomie exclusive rights for YCANTH in Israel By Investing.com - Investing.com Nigeria
Verrica grants Medomie exclusive rights for YCANTH in Israel - Investing.com
Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel - The Manila Times
Verrica deal could bring YCANTH to Israeli children if approved - Stock Titan
VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISI - GuruFocus
Verrica Pharmaceuticals (VRCA) Slides 4.13% as Resistance Holds FirmForce Index - dars.gov.et
Verrica Pharmaceuticals holds the spotlight after recent market context - ad-hoc-news.de
Q1 2026 Verrica Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
VRCAVerrica Pharmaceuticals Inc Latest SEC Filings - Finviz
VRCA News | VERRICA PHARMACEUTICALS INC (NASDAQ:VRCA) - ChartMill
Verrica Pharmaceuticals (VRCA) Rises 2% as Shares Test Resistance Near $6.36Sentiment Shift - dars.gov.et
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell 3000E Growth Benchmark - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell 3000E Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM: VRCA) added to Russell Microcap Index - marketscreener.com
Verrica Pharmaceuticals Inc.(NasdaqCM:VRCA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Number of shareholders of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Enterprise value to EBITDA forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Price to book forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Verrica Pharmaceuticals Inc. Cash Flow – DUS:1NE0 - TradingView
Price to sales forward of Verrica Pharmaceuticals Inc. – NASDAQ:VRCA - TradingView
Enterprise value to revenue forward of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Price to earnings ratio of Verrica Pharmaceuticals Inc. – DUS:1NE0 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (NASDAQ:VRCA) - TradingView
VRCA Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Pharmaceuticals Inc. Actuals & Estimates (SWB:1NE0) - TradingView
1NE0 Forecast — Price Target — Prediction for 2027 - TradingView
A41A98 Forecast — Price Target — Prediction for 2027 - TradingView
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion - MyChesCo
Verrica Pharmaceuticals (VRCA) Surges 6%: Momentum Builds Above Key SupportCash Flow Strong Stocks - dars.gov.et
Verrica Pharmaceuticals Inc (VRCA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
H.C. Wainwright reiterates Verrica stock rating on trial progress - Investing.com UK
Milestone Alert: First US Patient Dosed in the Second Phase 3 Trial of Verrica’s YCANTH for Common Warts - The Dermatology Digest
H.C. Wainwright reiterates Verrica stock rating on trial progress By Investing.com - Investing.com Australia
H.C. Wainwright Maintains Verrica Pharmaceuticals(VRCA.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Verrica doses first U.S. patient in common warts trial By Investing.com - Investing.com South Africa
Verrica doses first U.S. patient in common warts trial - Investing.com
Verrica starts Phase 3 common-warts trial with first U.S. patient - Stock Titan
Verrica doses first U.S. patient in Phase 3 tri... - Pluang
Verrica Pharmaceuticals Inc (VRCA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Verrica Pharmaceuticals Inc (VRCA) Institutional Confidence - TradingKey
Verrica Pharmaceuticals (VRCA) Holds Steady Near $6.0, Eyeing Resistance at $6.3Put Dominated - newsline.com
Verrica Pharmaceuticals Stockoperations and strategy in focus after YCANTH launch - Ad-hoc-news.de
Verrica’s COVE-3 Wart Study Moves Forward, Offering a Small but Notable Catalyst for VRCA and VEEV - TipRanks
Verrica Pharmaceuticals (NASDAQ: VRCA) director awarded 16,000 stock options at $6.04 - Stock Titan
Director at Verrica (NASDAQ: VRCA) receives 16,000 stock options - Stock Titan
1.97%
0.83%
자본화:
|
볼륨(24시간):